COMPASS Pathways PLC ADR (CMPS): Price and Financial Metrics
GET POWR RATINGS... FREE!
CMPS Stock Price Chart Interactive Chart >
CMPS Price/Volume Stats
|Current price||$12.21||52-week high||$49.51|
|Prev. close||$11.44||52-week low||$6.54|
|Day high||$12.28||Avg. volume||314,638|
|50-day MA||$9.34||Dividend yield||N/A|
|200-day MA||$19.51||Market Cap||519.06M|
COMPASS Pathways PLC ADR (CMPS) Company Bio
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Most Popular Stories View All
CMPS Latest News Stream
|Loading, please wait...|
CMPS Latest Social Stream
View Full CMPS Social Stream
Latest CMPS News From Around the Web
Below are the latest news stories about COMPASS Pathways plc that investors may wish to consider to help them evaluate CMPS as an investment opportunity.
The following slide deck was published by COMPASS Pathways plc in conjunction with their 2021 Q4 earnings call....
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
LONDON, United Kingdom, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Highlights: Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological supportPositive results from open-label study of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in TRDLaunch of phase II study of COMP360 psilocybin therapy for post-traumatic stress disorder
COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022
LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on 24 February 2022.
In this Backstage Pass segment, recorded on Feb. 4, Motley Fool contributor Rachel Warren discusses the psychedelic therapeutics market with Tim Schlidt, co-founder and partner at Palo Santo, a psychedelic investment fund. Schlidt explains that clinical milestones are the best way to gauge the health of this market going forward. Rachel Warren: What is one thing that we can all be watching to gauge the health of the psychedelic therapeutics market going forward?
A new review study by Johns Hopkins University researchers is shedding light on the long-term effects of psilocybin in the treatment of major depression. In a new study, 58% of participants with major depressive disorder were in remission after one year of doing two sessions with psilocybin. “Psilocybin not only produces significant and immediate effects, it also has a long duration, which suggests that it may be a uniquely useful new treatment for depression,” said Roland Griffiths , Ph.D., Professor in Neuropsychopharmacology of Consciousness at Johns Hopkins School of Medicine. Psilocybin, also known as the active compound in “magic mushrooms,” is one of the compounds spearheading a pipeline that looks to advance psychedelic drugs for medical use. There are currently dozens of biotec...
CMPS Price Returns